Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Aug;46(4):1182-1184.
doi: 10.1111/jcpt.13424. Epub 2021 Apr 5.

Therapeutic Bayesian monitoring of sunitinib in two patients with impaired absorption or elimination

Fanny Leenhardt  1   2   3 , Marie Viala  4 , Diego Tosi  3   4 , Emmanuelle Samalin-Scalzi  4 , Alexandre Evrard  2   3   5 , Litaty C Mbatchi  2   3   5
Affiliations
Case Reports

Therapeutic Bayesian monitoring of sunitinib in two patients with impaired absorption or elimination

Fanny Leenhardt et al. J Clin Pharm Ther. 2021 Aug.

Abstract

What is known and objective: Sunitinib pharmacokinetics can be influenced by the physio-pathological conditions of individual patients. Therapeutic drug monitoring (TDM) helps to optimize efficacy and reduce the risk of adverse effects. We report on the use of Bayesian analysis to optimize sunitinib blood levels.

Case summary: We describe two patients with risk of sunitinib pharmacokinetic variability due to gastrectomy and ongoing haemodialysis, respectively. TDM and Bayesian estimation allowed maintaining their sunitinib pharmacokinetic profiles within the usual limits.

What is new and conclusion: Our analysis showed that Bayesian analysis can be successfully applied for real-time TDM to optimize sunitinib blood levels in patients with major comorbidities.

PubMed Disclaimer

References

REFERENCES

    1. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2010;66:357-371.
    1. Numakura K, Fujiyama N, Takahashi M, et al. Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients. Oncotarget. 2018;9.
    1. Cabel L, Blanchet B, Thomas-Schoemann A, et al. Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study. Fundam Clin Pharmacol. 2018;32:98-107.
    1. de Wit D, van Erp NP, Khosravan R, et al. Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. BMC Cancer. 2014;14:575.
    1. EMA. SCIENTIFIC DISCUSSION Sutent 2006. https://www.ema.europa.eu/en/documents/scientific-discussion/sutent-epar... (accessed October 22, 2019).

Publication types

LinkOut - more resources